If you are looking at how melanoma treatment has changed, one of the biggest advances has been the development of immunotherapy. Advanced melanoma was once extremely difficult to control after it had spread or could no longer be removed surgically, but immune-based treatments opened the possibility of longer-lasting responses for some people.
Progress happened in stages. Early treatments such as interleukin-2 and interferon showed that the immune system could influence melanoma, while later discoveries involving CTLA-4 and PD-1 led to checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab. These milestones help explain why melanoma became so important in the development of modern cancer immunotherapy.
What Was the First Successful Melanoma Immunotherapy?
If you are wondering which treatment counts as the first successful melanoma immunotherapy, there is no single answer because “successful” can mean different things. In 1985, Steven Rosenberg and colleagues reported tumour regression after using immune cells activated in the laboratory, known as lymphokine-activated killer cells, together with recombinant IL-2. One patient with metastatic melanoma had a complete regression.
High-dose IL-2 was approved in the United States for adults with metastatic melanoma in January 1998. Ipilimumab represented a different milestone in 2010–2011 because it became the first immune-checkpoint treatment shown in a randomised phase III trial to extend overall survival in advanced melanoma.
Why Did Researchers Think Your Immune System Could Fight Melanoma?
Researchers discovered that your immune system could sometimes recognise melanoma cells, creating the possibility of strengthening this natural response through treatment. This suggested that the immune system might be able to play a role in controlling melanoma more effectively.
The challenge was finding a way to make this immune response strong enough and persistent enough to control advanced disease. Researchers therefore began looking for treatments that could help your immune system recognise melanoma cells more effectively and continue attacking them for longer.
How Did Early Cytokine Treatments Change Melanoma Care?
If you are trying to understand how modern melanoma immunotherapy developed, cytokines are an important part of the story. These signalling proteins help regulate your immune system. Before checkpoint inhibitors became available, doctors explored treatments such as interferon-alpha and interleukin-2 (IL-2), although the two medicines eventually had different roles in melanoma care.
If you look at these early treatments today, their importance was not that they worked for everyone, but that they showed immune-based treatment could sometimes control melanoma. High-dose IL-2 produced long-lasting complete tumour regression in a small number of people with metastatic melanoma, while interferon alfa-2b was used after surgery for selected people with high-risk disease. Both treatments had important limitations, including significant side effects and the relatively small proportion of patients who benefited.
How Did IL-2 Change What Was Possible for Some Patients?
If you are wondering why IL-2 became such an important milestone, it provided early evidence that immunotherapy could sometimes achieve long-term control of metastatic melanoma. Across eight trials involving 270 patients, 16% had an objective response, including complete responses in 6% and partial responses in 10%. Some complete responses lasted for many years, showing why the treatment attracted so much attention despite helping only a minority of patients.
How Did Immunotherapy Change Long-Term Survival?
The final 10-year CheckMate 067 results demonstrated how substantially the outlook for advanced melanoma had changed. With at least 10 years of follow-up, median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab alone and 19.9 months with ipilimumab alone.
These results show that some immunotherapy treatments can provide long-term benefit, but nivolumab plus ipilimumab is not automatically the best option for everyone. Your oncology team will consider factors such as your general health, risk of serious side effects, whether melanoma has spread to your brain, the characteristics of your tumour and your own treatment preferences.
Key Findings With High-Dose Interleukin-2
| Aspect | Finding | What It Showed | Why It Mattered |
| Patients studied | 270 patients across eight trials | Provided evidence from multiple clinical studies | Strengthened understanding of IL-2 activity |
| Overall response | 16% achieved an objective response | Some patients experienced measurable tumour reduction | Demonstrated potential for immunotherapy |
| Complete responses | 6% achieved complete responses | Some patients had no detectable disease after treatment | Showed the possibility of deep responses |
| Partial responses | 10% achieved partial responses | Tumour burden was reduced in some patients | Added further evidence of treatment activity |
| Long-term responses | Some complete responses persisted for many years | Responses could remain durable | Suggested immune treatment could provide prolonged disease control |
| Responses lasting over 30 months | No further disease progression was found during subsequent follow-up | Very durable control was possible in selected patients | Provided important evidence for lasting immunotherapy benefit |
Why IL-2 Was an Important Breakthrough
IL-2 helped show that stimulating the immune system could sometimes produce a long-lasting complete response even when melanoma had spread. This led to US approval of high-dose aldesleukin for adults with metastatic melanoma in January 1998.
If high-dose IL-2 had been considered for you, the potential benefits would have needed to be weighed carefully against the risks. Most patients did not respond, and treatment could cause severe side effects, so it required highly experienced specialist care. These limitations encouraged researchers to look for treatments that could offer a better balance between benefit and risk.
How Did Interferon Change Treatment After Melanoma Surgery?
Historically, if you had high-risk melanoma removed with surgery, interferon alfa-2b was one treatment that might have been considered afterwards. The ECOG E1684 randomised trial involved 287 patients and reported improvements in both relapse-free survival and overall survival with high-dose interferon compared with observation.
The study was published in 1996 and helped establish immunotherapy after melanoma surgery. If you need systemic treatment after surgery today, however, your options are very different because modern melanoma care has moved increasingly towards checkpoint inhibitors. Current NICE pathways now include newer checkpoint immunotherapies rather than interferon as the main systemic immunotherapy options.
Why Did Scientists Start Studying Immune Checkpoints?
Your immune system has natural “brakes” that help stop it from becoming overactive. Researchers began asking whether releasing some of these brakes could help your T cells recognise and attack cancer cells more effectively, which opened a completely different direction for melanoma treatment.
That idea changed the direction of melanoma research and eventually led to treatments that may be used in your care today. Checkpoint inhibitors work by removing specific restraints on immune activity, helping your immune system remain active against melanoma rather than simply stimulating it more strongly.
Why Did CTLA-4 Become a Crucial Target?
In 1996, experimental research showed that blocking CTLA-4 could strengthen anti-tumour immunity and cause established tumours to be rejected in mouse models. This provided important evidence that removing an immune “brake” could strengthen anti-tumour responses and helped pave the way for treatments that later used the same principle in people.
This discovery matters to modern treatment because it led researchers towards medicines that release an immune “brake” instead of directly attacking melanoma cells. If a checkpoint inhibitor is considered for you today, this same basic principle helps explain how treatment can support your immune system in recognising and attacking melanoma.
How Did Ipilimumab Bring Checkpoint Therapy Into Practice?
If ipilimumab is considered as part of your melanoma treatment, it works by blocking the CTLA-4 immune checkpoint. This removes one of the natural “brakes” on your immune system, giving immune cells a greater opportunity to recognise and attack melanoma cells.
The approach represented a major change in treatment because it focused on altering immune regulation rather than directly destroying melanoma cells with conventional chemotherapy. It helped establish immune checkpoint therapy as an important new direction in melanoma care.
Why Do Immune-Related Side Effects Matter for You?
Checkpoint inhibitors work by removing restraints on immune activity, so the same mechanism that helps your immune system attack melanoma can also cause harmful inflammation in healthy tissues. These reactions can sometimes be serious or life-threatening, and combination checkpoint treatment generally carries a higher risk of severe toxicity than PD-1 monotherapy.
If you are receiving immunotherapy, you should follow the advice given by your oncology team and report new or worsening symptoms promptly rather than waiting for your next routine appointment. Treatment choice and monitoring need to take your general health, potential benefit and tolerance of toxicity into account.
Why Was the 2010 Ipilimumab Trial So Important?
A landmark phase III trial published in 2010 evaluated ipilimumab in people with previously treated metastatic melanoma. Median overall survival was 10.1 months with ipilimumab alone and 10.0 months with ipilimumab plus the gp100 vaccine, compared with 6.4 months with gp100 alone.
This was a historic result because it showed that checkpoint immunotherapy could help some people with advanced melanoma live longer. It also showed why careful specialist care matters if this type of treatment is considered for you, because immune-related side effects can sometimes be severe and need prompt recognition and management.
What Happened After Ipilimumab Was Approved in 2011?
The US Food and Drug Administration approved ipilimumab for unresectable or metastatic melanoma on 25 March 2011. It became the first CTLA-4 checkpoint inhibitor approved for melanoma and helped establish checkpoint inhibition as an entirely new approach to systemic cancer treatment.
Unlike conventional chemotherapy, ipilimumab does not primarily work by directly poisoning melanoma cells. It blocks an inhibitory immune checkpoint, allowing T-cell responses against cancer to remain more active.
How Did the Discovery of PD-1 Change Melanoma Research?
Tasuku Honjo’s research group identified and cloned PD-1 in 1992. Its function as an inhibitory regulator of immune activity became clearer through later research, eventually establishing the PD-1/PD-L1 pathway as another important target for cancer immunotherapy.
A major 2012 clinical study of anti-PD-1 therapy reported objective responses in 28% of 94 people with melanoma, with many observed responses lasting at least a year. These findings provided strong early clinical evidence that PD-1 blockade could produce durable anti-tumour activity.
How Did Anti-PD-1 Treatments Improve Outcomes Further?
If nivolumab or pembrolizumab is considered for you, these medicines work by blocking PD-1 signalling so your immune system can remain active against melanoma. Clinical trials showed substantially better outcomes than were generally seen with older treatments. In previously untreated BRAF wild-type advanced melanoma, nivolumab produced a one-year overall-survival rate of 72.9% compared with 42.1% with dacarbazine in a phase III trial.
Pembrolizumab was later directly compared with ipilimumab in KEYNOTE-006. Longer follow-up showed superior overall survival with pembrolizumab, with 24-month overall survival of 55% compared with 43% in the ipilimumab group.
How Did Anti-PD-1 Therapy Reach Patients in 2014?
Pembrolizumab received its first US melanoma approval on 4 September 2014 for selected patients with unresectable or metastatic melanoma, followed by nivolumab on 22 December 2014. These approvals came only a few years after ipilimumab and accelerated the shift from older cytokine therapies towards immune-checkpoint blockade.
Since those first approvals, the roles of both medicines have expanded. If you are treated for melanoma today, PD-1 therapy may be considered in several settings depending on your melanoma stage, previous treatment and individual circumstances. This rapid development shows how quickly PD-1 blockade moved from research into modern melanoma care.
What Happened When Checkpoint Inhibitors Were Combined?
If combination immunotherapy is being considered for you, two different immune checkpoints may be targeted at the same time. Researchers investigated this approach by combining nivolumab with ipilimumab, and the CheckMate 067 trial showed longer progression-free and overall survival with the combination, and with nivolumab alone, compared with ipilimumab alone.
The potential benefit of combination therapy comes with substantially greater toxicity. In the initial trial report, treatment-related grade 3 or 4 adverse events occurred in 55% of participants receiving nivolumab plus ipilimumab compared with 16.3% receiving nivolumab alone. Your oncology team therefore needs to balance potential benefit against your individual risk of serious treatment-related toxicity.
Why Does Early Melanoma Detection Still Matter?
Even though immunotherapy has transformed treatment for advanced melanoma, early detection still matters greatly for you. If melanoma is found at an earlier stage, your treatment may be simpler and surgery may be the main treatment needed. Your treatment options and outlook depend heavily on the stage and characteristics of the melanoma.
If you are worried about a new or changing mole, arranging an assessment with an experienced dermatologist in London for a suspicious or changing skin lesion can help determine whether dermoscopic assessment, monitoring or biopsy is appropriate. Immunotherapy does not replace appropriate examination and histological assessment when melanoma is suspected.
What Does Current UK Guidance Mean for You?
If you have untreated stage IV or unresectable stage III melanoma in England, NICE recommends nivolumab plus ipilimumab when combination immunotherapy is suitable for you. If combination treatment is unsuitable or unacceptable, for example because of its potential toxicity, pembrolizumab or nivolumab monotherapy may be offered instead. NICE also recommends nivolumab–relatlimab as an option for untreated advanced melanoma in people aged 12 years and over under its specified conditions.
These treatments are delivered through specialist oncology care rather than as routine dermatology-clinic treatments. Your oncology team will consider your general health, how well you are day to day, the risk of serious side effects, whether melanoma has spread to your brain, tumour characteristics, previous treatment and your own preferences. Dermatologists continue to play an important role in recognising suspicious lesions, diagnosing melanoma and providing appropriate skin surveillance.
Myth vs Fact
| Myth | What You Should Know |
| One treatment was clearly the first successful melanoma immunotherapy. | Different milestones include early IL-2 responses, interferon in the adjuvant setting, IL-2 approval for metastatic melanoma and the later checkpoint-inhibitor survival breakthrough. |
| IL-2 worked for most patients. | If you had received high-dose IL-2, there was no guarantee of benefit. Historical pooled data showed complete responses in only about 6% of patients. |
| Ipilimumab directly kills melanoma cells. | It blocks CTLA-4 and changes the regulation of your immune response. |
| PD-1 was invented as a melanoma treatment. | PD-1 was discovered through basic immunology research in 1992; its cancer-treatment potential became clear later. |
| Combination immunotherapy is automatically best for everyone. | If combination immunotherapy is being considered for you, your oncology team will balance the potential for long-term benefit against the higher risk of serious side effects. |
| Immunotherapy only treats metastatic melanoma. | If you have had higher-risk melanoma removed surgically, checkpoint immunotherapy may also be considered afterwards in selected circumstances. |
| A successful immunotherapy response is guaranteed to last permanently. | Your response may sometimes last for many years, but immunotherapy cannot guarantee that melanoma will never return or progress. |
| Modern immunotherapy means early diagnosis matters less. | Early detection still matters for you because finding melanoma sooner can affect your treatment options and outlook. |
| A dermatologist normally chooses and administers advanced melanoma immunotherapy alone. | If you need advanced melanoma immunotherapy, your treatment decisions are made through specialist oncology and melanoma multidisciplinary care rather than by a dermatologist working alone. |
Key Takeaways
- Melanoma immunotherapy developed through several important breakthroughs rather than one single discovery.
- If you look back at early immunotherapy, IL-2 provided important evidence that stimulating the immune system could produce long-lasting complete responses in a small proportion of people with metastatic melanoma.
- Ipilimumab became the first checkpoint inhibitor shown in a randomised phase III trial to improve overall survival in advanced melanoma.
- If you need melanoma immunotherapy today, your options may include PD-1 inhibitors such as nivolumab or pembrolizumab, which began entering melanoma care in 2014.
- If nivolumab plus ipilimumab is suitable for you, the combination may provide substantial long-term benefit, but it also carries a higher risk of serious side effects.
- Nivolumab–relatlimab is another NICE-recommended option that may be considered if you have eligible untreated advanced melanoma.
- Even with modern immunotherapy available, early assessment still matters if you notice a suspicious or changing skin lesion, and your care may involve diagnosis, surgery and specialist oncology treatment where appropriate.
Frequently Asked Questions
1. What was the first successful immunotherapy for melanoma?
If you are asking which treatment should be called the first successful melanoma immunotherapy, there is no single universally correct answer. IL-2-based therapy produced some of the earliest documented durable regressions in metastatic melanoma during the 1980s, while high-dose IL-2 was approved for metastatic melanoma in 1998. Ipilimumab later became the first checkpoint inhibitor to demonstrate a randomised phase III overall-survival benefit.
2. How effective was high-dose IL-2 for metastatic melanoma?
If you are looking at how effective high-dose IL-2 actually was, the benefit was limited to a minority of patients. In a pooled series of 270 people, 16% had an objective response, including complete responses in 6%. Some complete responses lasted for many years, but most patients did not respond and treatment could cause severe side effects.
3. What was interferon used for in melanoma?
If you had high-risk melanoma removed surgically in the era before modern checkpoint treatments, high-dose interferon alfa-2b might have been considered afterwards. It became an important historical adjuvant treatment, although melanoma care has since changed considerably.
4. Why was ipilimumab such an important breakthrough?
If you are trying to understand why ipilimumab changed melanoma treatment, the key difference was that it targeted an immune checkpoint rather than directly attacking melanoma cells. A major 2010 trial showed that this approach could improve survival in advanced melanoma.
5. When was ipilimumab approved for melanoma?
The FDA approved ipilimumab for unresectable or metastatic melanoma on 25 March 2011.
6. What did the discovery of PD-1 change?
PD-1 was identified by Tasuku Honjo’s group in 1992. Subsequent research established it as an immune checkpoint, leading to drugs such as nivolumab and pembrolizumab that became major treatments for advanced melanoma.
7. Are nivolumab and pembrolizumab more effective than older immunotherapies?
Clinical trials showed that nivolumab and pembrolizumab improved outcomes compared with some older melanoma treatments. If either medicine is being considered for you, your oncology team will look at the evidence alongside your general health, melanoma characteristics and the potential benefits and risks of treatment.
8. Is nivolumab plus ipilimumab suitable for everyone?
No. If combination immunotherapy is being considered for you, your oncology team will weigh the potential long-term benefit against the greater risk of serious side effects. If the combination is unsuitable or unacceptable for you, PD-1 monotherapy may be considered instead.
9. Can immunotherapy help after melanoma surgery?
Yes. If you have had higher-risk melanoma removed surgically, immunotherapy may sometimes be considered afterwards to reduce the risk of the cancer returning. Whether it is suitable for you will depend on your melanoma stage and the current treatment criteria.
10. Does immunotherapy mean a changing mole can wait?
No. If you notice a new or changing mole, you should not delay getting it assessed because immunotherapy is available. Your dermatologist may examine the lesion with a dermatoscope and, if melanoma is suspected, you may need a biopsy or removal of the lesion so it can be examined properly.
Final Thoughts: How Melanoma Immunotherapy Changed Cancer Care
If you are reading about melanoma treatment today, the options available are very different from those of a few decades ago. Early treatments such as IL-2 and interferon showed that the immune system could sometimes help control melanoma, while checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab transformed treatment for many people with advanced disease
If you’d like to book a consultation with one of our dermatologists in London, you can contact us at the London Dermatology Centre.
References:
- Atkins, M.B., Kunkel, L., Sznol, M. and Rosenberg, S.A. (2000) ‘High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update’, Cancer Journal from Scientific American, 6(Suppl. 1), pp. S11–S14. Available at: https://pubmed.ncbi.nlm.nih.gov/10685652/
- Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C. and Blum, R.H. (1996) ‘Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684’, Journal of Clinical Oncology, 14(1), pp. 7–17. Available at: https://pubmed.ncbi.nlm.nih.gov/8558223/
- Topalian, S.L. et al. (2012) ‘Safety, activity, and immune correlates of anti-PD-1 antibody in cancer’, New England Journal of Medicine, 366(26), pp. 2443–2454. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3544539/
- Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.J., Mortier, L. et al. (2017) ‘Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)’, The Lancet, 390(10105), pp. 1853–1862. Available at: https://pubmed.ncbi.nlm.nih.gov/28822576/
- Wolchok, J.D. et al. (2025) ‘Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma’, New England Journal of Medicine, 392(1), pp. 11–22. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080919/